FlotoReview
SPAC

424B4 Prospectus: RACC Merger Values Oak Hill Bio at $160M

Research Alliance Corp III filed its 424B4 prospectus for the Oak Hill Bio merger: $160M base equity value, $55M PIPE, a $75M backstop and a Nov. 24 vote.

Nov 4, 20264 min read
4min read
1sources
4topics
Nov 4published
Laboratory glassware and equipment in a biotechnology research lab
Laboratory glassware and equipment in a biotechnology research lab. Image: Alessiocoser via wikimedia (CC BY 4.0)

Research Alliance Corp III (Nasdaq: RACC), a Cayman Islands blank-check company sponsored by affiliates of RA Capital, filed a 424B4 prospectus on November 4 that doubles as the proxy statement for its planned combination with OHB Pediatrics Ltd., the clinical-stage biotechnology company known as Oak Hill Bio. The document sets a shareholder meeting for November 24 and lays out the money that will sit behind the merged company if the deal closes.

Key takeaways

  • The business combination agreement, signed July 26, 2026, values Oak Hill Bio at a base equity value of $160 million, paid in new shares at $10.00 each.
  • Investors have committed $55 million in a PIPE, and an RA Capital affiliate has agreed to backstop redemptions with up to $75 million.
  • RACC shareholders vote at 10:00 a.m. Eastern on November 24; redemption requests are due by November 20.
  • The combined company would be renamed Oak Hill Bio Inc. and apply to list on Nasdaq under the symbol OAKH.

What the 424B4 prospectus says about deal terms

The filing registers up to 9,098,529 shares of common stock of RACC after it domesticates as a Delaware corporation. Under the agreement, RACC acquires 100% of Oak Hill Bio from its shareholders in exchange for new shares. The number of shares issued equals the adjusted equity value divided by $10.00. Adjusted equity value is the $160 million base plus the Oak Hill Bio SAFE amount, which is the principal and accrued interest on $45 million of simple agreements for future equity.

Those SAFEs were issued on July 26 by RA Capital Healthcare Fund and RA Capital Nexus Fund IV, both affiliates of RACC’s sponsor, and carry interest at 8% a year. They convert into Oak Hill Bio ordinary shares just before closing. The filing says Oak Hill Bio shareholders, including the SAFE holders and option holders, will receive an aggregate of 16,000,000 shares based on the $160 million base value.

ItemFigure in the filing
Base equity value$160,000,000
Oak Hill Bio SAFEs (8% interest)$45,000,000 principal
PIPE financing$55,000,000 (5,500,000 shares at $10.00)
Sponsor-affiliate backstopUp to 7,500,000 shares, capped at $75,000,000
Trust account, June 30, 2026$75,238,468
Estimated redemption priceAbout $10.03 a share

Funding and redemption protection

SPAC mergers often turn on how many public holders redeem for cash. RACC’s initial public offering on May 21, 2026 sold 7,500,000 shares at $10.00 and put $75 million in trust. The backstop agreement with RA Capital Healthcare Fund commits that fund to buy up to 7,500,000 new shares at $10.00 to the extent redemptions need to be covered, and the amount it must fund cannot exceed $75 million. The limit shrinks by the number of shares that are not redeemed.

The PIPE adds a separate layer. Subscribers may take common stock or pre-funded warrants priced at $10.00 less a $0.0001 exercise price, and their obligation depends on Nasdaq conditionally approving the new shares for listing.

On October 29, the most recent date cited, RACC shares closed at $10.10, compared with $11.02 on July 24, the last full trading day before the deal was announced.

The prospectus is direct about the sponsor’s position. The sponsor paid $25,000 for 1,323,529 Class B shares, roughly $0.02 each, and 1,245,269 of those shares, plus 78,260 held by two independent directors, will convert one-for-one into Class A shares and then into new common stock. The sponsor also bought 275,000 Class A shares at $10.00 in a private placement. Because of the low founder-share cost, the filing says the sponsor could earn a positive return even if the stock trades below $10.00, while public holders could lose money. Public shareholders own about 82.4% of RACC’s shares before the transaction and will be diluted by it.

The target

Oak Hill Bio describes itself as a company focused on acquiring and developing rare-disease therapies that larger drugmakers have deprioritized. Its lead program, rugonersen (OHB-724), is an antisense oligonucleotide in Phase 3 development for Angelman syndrome. The Phase 3 BEACON trial began in June 2026 and is enrolling. The filing estimates about 30,000 diagnosed patients in the United States and five major EU markets and notes there are no approved disease-modifying therapies.

What to watch

The November 20 redemption deadline and the November 24 vote will show how much of the $75 million trust remains. The size of any redemptions determines how much the backstop is drawn and how much cash reaches Oak Hill Bio, whose filing says it will need additional capital to complete development. For readers tracking SPAC deals, the useful comparison is not the headline valuation but the layering of the SAFE, PIPE and backstop on top of the trust.

Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.

Related